We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Eli Lilly (LLY) Stock Sinks As Market Gains: What You Should Know
Read MoreHide Full Article
Eli Lilly (LLY - Free Report) closed at $359.12 in the latest trading session, marking a -0.36% move from the prior day. This change lagged the S&P 500's 0.34% gain on the day. At the same time, the Dow added 0.64%, and the tech-heavy Nasdaq gained 8.98%.
Coming into today, shares of the drugmaker had lost 0.85% in the past month. In that same time, the Medical sector lost 0.28%, while the S&P 500 gained 1%.
Eli Lilly will be looking to display strength as it nears its next earnings release, which is expected to be February 2, 2023. The company is expected to report EPS of $1.91, down 23.29% from the prior-year quarter. Meanwhile, our latest consensus estimate is calling for revenue of $7.31 billion, down 8.63% from the prior-year quarter.
Investors should also note any recent changes to analyst estimates for Eli Lilly. These revisions help to show the ever-changing nature of near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Based on our research, we believe these estimate revisions are directly related to near-team stock moves. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 10.49% lower. Eli Lilly is currently sporting a Zacks Rank of #5 (Strong Sell).
Looking at its valuation, Eli Lilly is holding a Forward P/E ratio of 42.57. This represents a premium compared to its industry's average Forward P/E of 14.55.
Also, we should mention that LLY has a PEG ratio of 2.15. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. The Large Cap Pharmaceuticals industry currently had an average PEG ratio of 1.7 as of yesterday's close.
The Large Cap Pharmaceuticals industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 144, which puts it in the bottom 43% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks.com to follow all of these stock-moving metrics, and more, in the coming trading sessions.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Eli Lilly (LLY) Stock Sinks As Market Gains: What You Should Know
Eli Lilly (LLY - Free Report) closed at $359.12 in the latest trading session, marking a -0.36% move from the prior day. This change lagged the S&P 500's 0.34% gain on the day. At the same time, the Dow added 0.64%, and the tech-heavy Nasdaq gained 8.98%.
Coming into today, shares of the drugmaker had lost 0.85% in the past month. In that same time, the Medical sector lost 0.28%, while the S&P 500 gained 1%.
Eli Lilly will be looking to display strength as it nears its next earnings release, which is expected to be February 2, 2023. The company is expected to report EPS of $1.91, down 23.29% from the prior-year quarter. Meanwhile, our latest consensus estimate is calling for revenue of $7.31 billion, down 8.63% from the prior-year quarter.
Investors should also note any recent changes to analyst estimates for Eli Lilly. These revisions help to show the ever-changing nature of near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Based on our research, we believe these estimate revisions are directly related to near-team stock moves. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 10.49% lower. Eli Lilly is currently sporting a Zacks Rank of #5 (Strong Sell).
Looking at its valuation, Eli Lilly is holding a Forward P/E ratio of 42.57. This represents a premium compared to its industry's average Forward P/E of 14.55.
Also, we should mention that LLY has a PEG ratio of 2.15. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. The Large Cap Pharmaceuticals industry currently had an average PEG ratio of 1.7 as of yesterday's close.
The Large Cap Pharmaceuticals industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 144, which puts it in the bottom 43% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks.com to follow all of these stock-moving metrics, and more, in the coming trading sessions.